Li-Fraumeni Syndrome: Characterization of a Pediatric Cohort from a Pediatric Oncology Center

Background: Li-Fraumeni syndrome (LFS) is a hereditary cancer predisposition syndrome caused by germline pathogenic variants in the TP53 gene. Carriers have high predisposition to multiple malignancies, frequently presenting during childhood. Identification of carriers allows implementation of surveillance programs and tailored treatments, minimizing exposure to radiotherapy and other potentially toxic agents.

Methods: This retrospective, observational, descriptive study included patients diagnosed with LFS before 18 years of age, followed at a Pediatric Oncology Department. We analyzed TP53 variants, demographics, family history, tumor occurrence and type, fulfillment of Chompret criteria, surveillance strategies and clinical outcomes.

Results: Pathogenic/likely pathogenic TP53 variants were identified in 18 patients, 11 (61%) female, with median age at molecular diagnosis of LFS of 11.5 years. The variant was de novo in six patients (33%), maternally inherited in six and paternally inherited in six. The R337H variant was identified in seven patients. Nine patients (50%) were found to be carriers before any malignancy, through cascade family screening and remain cancer-free. In the remaining patients, molecular diagnosis followed the first tumor in five (28%) and second tumor in four (22%). One patient, received radiotherapy during treatment of first malignancy, before being diagnosed with LFS after a second tumor. Cancer screening in healthy individuals followed the Toronto Protocol. Two patients were lost to follow-up. Two patients had documented psychological follow-up. Among patients diagnosed with cancer, five remain under follow-up, two have transitioned to adult care, and two have died - one at 17 years of age after four primary tumors, from high-grade glioma at 4 years to osteosarcoma at 16 years; and another at 4 years, nine months after diagnosis of high-grade glioma. Eight patients (89%) diagnosed with cancer met Chompret criteria: three at the time of the first tumor, four at the second tumor and one could not be assessed due to lack of clinical data. Six patients had somatic TP53 variant identified in their tumor, prompting germline testing that confirmed the same variant in the germline. In five of these patients, the variant was de novo; one was an index case diagnosed at two years of age, leading to the identification of other carriers in the family. One patient underwent germline testing only after a second tumor. Two patients, treated for adrenocarcinoma and pilocytic astrocytoma at one year of age, had not undergone genetic testing at the time (2003 and 2012). These patients were subsequently diagnosed with LFS after relatives developed cancer, leading to identification of additional carriers within the family.

Conclusions: Somatic TP53 variants may prompt germline testing and facilitate genetic counselling, as supported in our small cohort. Identifying LFS carriers is essential to enable tailored treatment and minimize treatment-related harm, particularly avoiding radiotherapy when possible. However, treatment options may be limited for certain tumors, and radiotherapy may still be necessary when no effective alternative is available. LFS surveillance protocols can impose a significant psychological burden. Despite their proven benefits in early cancer detection and patient outcomes, this impact should not be overlooked, as it may reduce adherence to surveillance.